Clinical trials: Cardiac Event
- Condition Cardiac Event
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Hypercholesterolemia
The Occurrence of MACE in Patients With AMI Receiving Pitavastatin/Valsartan Treatment
Prospective Observation study to identify the rate of MACE in AMI with Livalo V(Pitavastatin/Valsartan) for 12 month in Korea
- Trial name
- LAMISIII (NCT04270344)
- Testing
- Pitavastatin 4mg
- Where
- South Korea
- Volunteers
- 905 people, healthy volunteers welcome
- Sponsor
- JW Pharmaceutical
Cardiac Arrhythmia
True Continuous ECG Monitoring (TCEM Study)
The purpose of this study is to compare short term (up to 48 hours) traditional cardiac rhythm monitoring using a standard ambulatory Holter monitor versus long term (up to 14 days), continuous ambulatory cardiac rhythm…
- Trial name
- TCEM (NCT01559246)
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- iRhythm Technologies, Inc.
Heart Failure, Congestive
Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease
The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcome in subjects with heart failure and in comparison to subjects without cardiovascular disease.
- Trial name
- NCT00126438
- Testing
- 123I-mIBG (meta-iodobenzylguanidine)
- Where
- United States
- Volunteers
- 515 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Neurodegenerative Diseases, Osteoarthritis
Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions
To evaluate for any adverse effects that may be related to the administration and reception of autologous adipose derived stromal vascular fraction (SVF).
- Conditions
- Neurodegenerative Diseases, Osteoarthritis, Erectile Dysfunction, Autoimmune Diseases
- Trial name
- NCT01953523
- Testing
- Administration of autologous adipose derived SVF
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Elliot Lander
Heart Failure, Congestive
Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease
The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcomes in subjects with heart failure and in comparison to subjects without cardiovascular disease.
- Trial name
- NCT00126425
- Testing
- 123I-mIBG (meta-iodobenzylguanidine)
- Where
- United States
- Volunteers
- 587 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Prevention of Thromboembolic Events, Atrial Fibrillation
A Study to Learn How the Study Treatment Asundexian Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body in Participants With Mild or Moderate Reduction of Liver Function Compared to Participants With Normal Liver Function
Researchers are looking for a better way to prevent the formation of blood clots in people who have or have had: an irregular and often rapid heartbeat a blocked blood flow to the heart a blocked or reduced blood flow to a part…
- Conditions
- Prevention of Thromboembolic Events, Atrial Fibrillation, Acute Myocardial Infarction, Non-cardioembolic Ischemic Stroke
- Trial name
- NCT05419635
- Testing
- Asundexian (BAY2433334)
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bayer
Acute Kidney Injury
Controlled Trial to Demonstrate a Reduction in the Number of Oliguria Events in Patients Being Managed in a Critical Care Unit, Following Cardiac Surgery, When a Novel Oliguria Prediction Tool (STABILITY UO) is Used to Identify Patients at Risk, Compared to Standard of Care.
Acute kidney injury (AKI) is experienced by 12% of patients following surgery and in up to 50% of patients following cardiac surgery.
- Trial name
- NCT05001503
- Testing
- Stability UO
- Where
- United Kingdom
- Volunteers
- 362 people, healthy volunteers welcome
- Sponsor
- Rinicare Ltd
Cardiac Event
PREVENT - Prospective Rhythm Event Surveillance in the ER With NetGuard
The purpose of this study is to determine the incidence of clinically significant rhythm and rate changes in ED patients who are not placed on conventional telemetry, and to test the user-friendliness of a automated clinician…
- Trial name
- PREVENT (NCT00750958)
- Testing
- NetGuard Automated Clinician Alert System
- Where
- 2 sites in United States
- Volunteers
- 287 people, healthy volunteers welcome
- Sponsor
- Datascope Patient Monitoring
Orthopedic Disorder, Neurologic Disorder
Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions
To determine the safety and efficacy of Amniotic and Umbilical Cord Tissue for the treatment of the following condition categories: Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions.
- Conditions
- Orthopedic Disorder, Neurologic Disorder, Urologic Diseases, Erectile Dysfunction
- Trial name
- NCT03899298
- Testing
- Amniotic and Umbilical Cord Tissue Procedure
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- R3 Stem Cell
Smoking Cessation
Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.
Non-treatment extension to study A3051123, aimed at collecting data on cardiovascular safety for all participants in the A3051123 trial for an additional 28 weeks, allowing for a total of 52 weeks of cardiovascular safety data…
- Trial name
- CATS (NCT01574703)
- Testing
- varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
- Where
- 134 sites in United States, Argentina and 14 more
- Volunteers
- 4,595 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2, PreDiabetes
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease.
- Conditions
- Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
- Trial name
- TRANSFORM (NCT06112418)
- Testing
- The Cleerly CAD Staging System
- Where
- 125 sites in United States
- Volunteers
- 7,500 people, healthy volunteers welcome
- Sponsor
- Cleerly, Inc.
Sickle Cell Disease
A Study to Compare if the Uptake of Ticagrelor in the Body Differs When Different Tablets Are Administered
To evaluate the relative bioavailability of ticagrelor for the different formulations. A randomized cross-over design has been chosen to minimize the effects of between-subject variability and any period effects on the overall…
- Trial name
- NCT03126695
- Testing
- Ticagrelor granule, Ticagrelor pediatric tablets, Ticagrelor pediatric tablets suspended in water
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Atrial Fibrillation
A Study to Investigate if Early Atrial Fibrillation (AF) Diagnosis Reduces Risk of Events Like Stroke in the Real-World
The primary objectives of this study are to identify and diagnose Atrial Fibrillation (AF), evaluate improvement in cardiovascular (CV) outcomes, improve direct oral anti-coagulant (DOAC) adherence and persistence, and better…
- Trial name
- NCT04276441
- Testing
- Heart healthy Engagement Program with the Apple Watch Series 5 or later, Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later
- Where
- United States
- Volunteers
- 34,244 people, healthy volunteers welcome
- Sponsor
- Janssen Scientific Affairs, LLC